Novo Nordisk AS Newswire (Page 4)

Novo Nordisk AS Newswire (Page 4)

Comprehensive Real-Time News Feed for Novo Nordisk AS. (Page 4)

Results 61 - 80 of 1,005 in Novo Nordisk AS

  1. RPT-UPDATE 2-U.S. FDA panel recommends approval of Novo Nordisk diabetes drugRead the original story

    May 24, 2016 | Reuters

    May 24 A U.S. advisory panel on Tuesday recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combination designed to be both effective and convenient. The panel voted 16-0 that the Food and Drug Administration should approve the drug, iDegLira, for patients with type 2 diabetes.

    Comment?

  2. IDegLira receives unanimous 16-0 vote in favor of approval from FDA Advisory CommitteeRead the original story

    May 24, 2016 | Freshnews

    Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of Tresiba and Victoza injection for the treatment of adults with type 2 diabetes.

    Comment?

  3. IDegLira Receives Positive 16-0 Vote in Favour of Approval from FDA Advisory CommitteeRead the original story w/Photo

    May 23, 2016 | Drugs.com

    Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of insulin degludec and liraglutide for the treatment of adults with type 2 diabetes.

    Comment?

  4. UPDATE 1-U.S. FDA panel recommends approval of Novo Nordisk diabetes drugRead the original story

    May 24, 2016 | Reuters

    A U.S. advisory panel on Tuesday recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combination designed to be both effective and convenient. The panel voted 16-0 that the Food and Drug Administration should approve the drug, iDegLira, for patients with type 2 diabetes.

    Comment?

  5. Experts Urge Surgery To Cure Type-2 DiabetesRead the original story w/Photo

    May 24, 2016 | Sky News

    Up to 100,000 people in the UK should be offered weight-loss surgery in the hope of curing their diabetes, world experts have said. A leading group of international diabetes organisations, including Diabetes UK, says the evidence is now so strong that obesity surgery can also reverse type-2 diabetes that it should be considered a standard treatment option.

    Comment?

  6. Novo Nordisk A/S (NVO) Stake Maintained by Saddle Road Partners LLCRead the original story w/Photo

    May 24, 2016 | Daily Political

    Saddle Road Partners LLC continued to hold its position in Novo Nordisk A/S during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 10,000 shares of the company's stock at the end of the first quarter.

    Comment?

  7. Businesses That Win Trait No. 3: Long-Term ThinkingRead the original story w/Photo

    May 24, 2016 | The Motley Fool

    As deadlines approach and pressure builds, businesses and investors can become increasingly tempted to go for short-term gains. However, businesses that win orient themselves to a long-term vision and base their practices on it.

    Comment?

  8. Slim pickings in weight-loss drug marketRead the original story w/Photo

    May 23, 2016 | Boston.com

    The pill, approved in 2014, was once projected as a shoo-in blockbuster: With more than one-third of Americans obese, the market seemed ripe for a pharmaceutical that promotes weight loss. Yet today, Orexigen, which is based here in Southern California, is on the brink of a Nasdaq delisting, with shares trading below 50 cents.

    Comment?

  9. FDA Advisors Question Study Findings for Diabetes Drug IDegLiraRead the original story

    May 23, 2016 | P&T Community

    The FDA has published a briefing document ahead of the May 24 meeting of its Endocrinologic and Metabolic Drugs Advisory Committee to discuss the new drug application for IDegLira , a fixed-dose combination of insulin degludec and liraglutide . The product's proposed indication is as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.

    Comment?

  10. Semaglutide significantly reduces the risk of major adverse...Read the original story w/Photo

    Apr 27, 2016 | Drugs.com

    Novo Nordisk today announced the top-line results from the sixth and last global phase 3a trial, SUSTAIN6, for semaglutide; a new GLP-1 analogue, which is administered subcutaneously once weekly in the SUSTAIN trials. This double-blinded trial investigated the long-term cardiovascular and other safety outcomes of 0.5 mg and 1.0 mg semaglutide compared with placebo, both in addition to standard-of-care.

    Comment?

  11. Monthly News Roundup - September 2015Read the original story w/Photo

    Sep 30, 2015 | Drugs.com

    This month, the U.S. Food and Drug Administration approved two new insulins from Novo Nordisk: Tresiba and Ryzodeg 70/30 to improve blood sugar control in adults with diabetes mellitus. Tresiba is a long-acting insulin injected once daily, while Ryzodeg is a mixture of long-acting and rapid-acting insulin analogs.

    Comment?

  12. Bath Savings Trust Co Sells 1,445 Shares of Novo Nordisk A/SRead the original story w/Photo

    May 18, 2016 | Daily Political

    Bath Savings Trust Co lowered its stake in Novo Nordisk A/S by 2.3% during the first quarter, Holdings Channel reports. The institutional investor owned 62,670 shares of the company's stock after selling 1,445 shares during the period.

    Comment?

  13. Novo Nordisk, Chip Ganassi Racing Teams and Charlie Kimball Honor the ...Read the original story

    May 17, 2016 | Paddock Talk

    Chip Ganassi Racing Teams and longtime partner Novo Nordisk, a world leader in diabetes care, along with their Verizon IndyCar Series driver Charlie Kimball, will join together to honor the diabetes community at the 100th running of the Indianapolis 500. Novo Nordisk Chip Ganassi Racing will change the number of Kimball's Tresiba Chevrolet from its usual No.

    Comment?

  14. Arena Investors: What To Consider As Anti-Obesity Drugs FizzleRead the original story w/Photo

    May 16, 2016 | Seeking Alpha

    About 5 years ago when a few companies were still in clinical trials for new branded anti-obesity pills analysts looked at the potential market and felt that approval may lead to blockbuster sales, a solution to the obesity epidemic, and investment accounts that were sure to grow. The positive thoughts led Arena to partner its drug candidate Belviq with Eisai in a very healthy deal.

    Comment?

  15. Long-Acting Factor IX Product Submitted for Regulatory ReviewRead the original story

    May 16, 2016 | P&T Community

    Novo Nordisk has announced the submission to the FDA of a biologics license application for the approval of nonacog beta pegol, a long-acting glycopegylated recombinant factor IX developed for patients with hemophilia B. The filing of nonacog beta pegol was based on positive results from the paradigm clinical trial program, which involved 115 patients with severe or moderately severe hemophilia B. Nonacog beta pegol was found to be efficacious in routine prophylaxis, in the treatment of bleeding episodes, and during surgery in adults, adolescents, and children. Moreover, nonacog beta pegol appeared to be well tolerated and no safety concerns were identified.

    Comment?

  16. Novo Nordisk, Chip Ganassi Racing Teams and Charlie Kimball Honor the Diabetes Community...Read the original story w/Photo

    May 16, 2016 | Freshnews

    Chip Ganassi Racing Teams and longtime partner Novo Nordisk, a world leader in diabetes care, along with their Verizon IndyCar Series driver Charlie Kimball, will join together to honor the diabetes community at the 100th running of the Indianapolis 500. Novo Nordisk Chip Ganassi Racing will change the number of Kimball's Tresiba Chevrolet from its usual No.

    Comment?

  17. Novo files BLA with FDA for long-acting factor IX for hemophilia BRead the original story w/Photo

    May 16, 2016 | Seeking Alpha

    Novo Nordisk submits its Biologics License Application to the FDA seeking approval of its long-acting factor IX, nonacog beta pegol, for the treatment of patients with hemophilia B. The glycopegylated recombinant factor IX has a 5x longer half-life than standard factor IX products which enables once-weekly dosing.

    Comment?

  18. Novo Nordisk files for regulatory approval in the US of long-acting...Read the original story w/Photo

    May 16, 2016 | GlobeNewswire

    BagsvA rd, Denmark, 16 May 2016 - Novo Nordisk today announced the submission to the US Food and Drug Administration of the Biologics License Application for the approval of long-acting factor IX, nonacog beta pegol. Nonacog beta pegol is a glycopegylated recombinant factor IX with a significantly improved pharmacokinetic profile, developed for patients with haemophilia B. The filing of nonacog beta pegol is based on the results from the paradigm clinical trial programme which involved 115 patients with severe or moderately severe haemophilia B. Nonacog beta pegol was found to be efficacious in routine prophylaxis, treatment of bleeding episodes and surgery for adults, adolescents and children.

    Comment?

  19. Novo Nordisk A/S, Chip Ganassi Racing Teams And Charlie Kimball Honor ...Read the original story w/Photo

    May 15, 2016 | BioSpace

    Novo Nordisk A/S , Chip Ganassi Racing Teams And Charlie Kimball Honor The Diabetes Community With The No. 42 Tresiba Chevrolet At The 100th Running Of The Indianapolis 500 /PRNewswire/ -- Chip Ganassi Racing Teams and longtime partner Novo Nordisk, a world leader in diabetes care, along with their Verizon IndyCar Series driver Novo Nordisk Chip Ganassi Racing will change the number of Kimball's TresibaA Chevrolet from its usual No.

    Comment?

  20. Sport24.co.za | Sagan opens Tour of California with winRead the original story w/Photo

    May 16, 2016 | News24

    Reigning champion Peter Sagan extended his Tour of California stage victories record on Sunday as he opened the defence of his crown with a win. The Slovak Tinkoff rider sprinted to victory in the 170.5km first stage held in and around San Diego, finishing clear of Dutch duo Wouter Wippert and Dylan Groenewegen.

    Comment?